C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Purchases Shares of 10,395 Koninklijke Philips (NYSE:PHG)

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in Koninklijke Philips (NYSE:PHG) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 10,395 shares of the technology company’s stock, valued at approximately $263,000.

A number of other hedge funds have also recently bought and sold shares of PHG. Bank of Montreal Can boosted its stake in shares of Koninklijke Philips by 2,883.5% during the 3rd quarter. Bank of Montreal Can now owns 982,199 shares of the technology company’s stock worth $32,157,000 after acquiring an additional 949,278 shares during the period. IHT Wealth Management LLC bought a new position in shares of Koninklijke Philips during the 3rd quarter worth approximately $19,593,000. JPMorgan Chase & Co. boosted its stake in shares of Koninklijke Philips by 315.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 245,729 shares of the technology company’s stock worth $8,040,000 after acquiring an additional 186,520 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Koninklijke Philips during the 3rd quarter worth approximately $4,622,000. Finally, Jane Street Group LLC boosted its stake in shares of Koninklijke Philips by 787.9% during the 3rd quarter. Jane Street Group LLC now owns 128,686 shares of the technology company’s stock worth $4,211,000 after acquiring an additional 114,193 shares during the period. 13.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently commented on the company. StockNews.com upgraded Koninklijke Philips from a “hold” rating to a “buy” rating in a research note on Thursday. Jefferies Financial Group raised Koninklijke Philips from an “underperform” rating to a “hold” rating in a report on Tuesday, October 29th. Finally, UBS Group raised Koninklijke Philips from a “neutral” rating to a “buy” rating in a report on Thursday. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Koninklijke Philips presently has an average rating of “Moderate Buy”.

Koninklijke Philips Price Performance

Koninklijke Philips stock opened at $25.04 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.74 and a current ratio of 1.16. Koninklijke Philips has a 52 week low of $19.55 and a 52 week high of $32.91. The stock has a market capitalization of $23.53 billion, a P/E ratio of -59.61, a price-to-earnings-growth ratio of 0.93 and a beta of 0.77. The stock has a fifty day moving average of $26.25 and a 200-day moving average of $28.16.

Koninklijke Philips (NYSE:PHG) last posted its quarterly earnings results on Wednesday, February 19th. The technology company reported $0.54 EPS for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.01). Koninklijke Philips had a positive return on equity of 10.11% and a negative net margin of 1.83%. The business had revenue of $5.38 billion for the quarter, compared to analyst estimates of $5.10 billion. On average, sell-side analysts expect that Koninklijke Philips will post 1.43 earnings per share for the current fiscal year.

Koninklijke Philips Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.